| ¿µ¹® | serum enzyme | ÇÑ±Û | Ç÷ûȿ¼Ò |
|---|---|---|---|
| ¼³¸í | Ç÷û ³»¿¡ Æ÷ÇԵǾî ÀÖ´Â ¿©·¯ °¡Áö È¿¼Ò¸¦ ÀÏÄ´ ¸»ÀÌ´Ù. |
||
| ¿µ¹® | enzyme | ÇÑ±Û | È¿¼Ò |
|---|---|---|---|
| ¼³¸í | »ý¹°Ã¼ ¼¼Æ÷¼Ó¿¡¼ ÇÕ¼ºµÇ°í, ÁÖ·Î ¼¼Æ÷³»¿¡¼ ÁøÇàµÇ´Â ÈÇйÝÀÀÀ» Ã˸ÅÇÏ´Â ´Ü¹éÁú·Î ½ÃÇè°ü³»¿¡¼µµ °°Àº Ã˸ÅÀÛ¿ëÀ» ÇÑ´Ù. ÀÌ È¿¼Ò´Â ÀΰøÀûÀ¸·Î ¸¸µç ¾î¶² Ã˸ÅÁ¦º¸´Ù ±× ƯÀ̼º°ú Ã˸ÅÀÛ¿ëÀÌ Å¹¿ùÇÑ Æ¯º°ÇÑ »ýüºÐÀÚÀÌ´Ù. ½ÅÁø´ë»ç, Áï ¼¼Æ÷³»¿¡¼ ÀϾ´Â ¹°ÁúÀÇ ÈÇÐÀû º¯È¯Àº È¿¼ÒÀÇ ÀÛ¿ë¿¡ ÀÇÇØ ¸Å¿ì ºü¸£°í ¿øÇÒÇÏ°Ô ÀÌ·ç¾îÁø´Ù. À̰ÍÀº È¿¼ÒÀÇ Ã˸ŠȿÀ²ÀÌ ³ôÀº Á¡°ú È¿¼ÒÀÇ ±âÁú ƯÀ̼º ¶§¹®ÀÌ´Ù. È¿¼Ò¹ÝÀÀÀº »ó¿Â, »ó¾Ð, ÃÖÀû pH µî ÀûÀýÇÑ Á¶°Ç ¾Æ·¡¿¡¼ ÁøÇàµÈ´Ù. ¶Ç È¿¼ÒÀÇ ÁÖü°¡ ´Ü¹éÁúÀ̱⠶§¹®¿¡ ´Ü¹éÁúÀ» º¯¼º½ÃŰ´Â ¿, °»ê, °¾ËÄ®¸®, À¯±â¿ë¸Å µî¿¡ ÀÇÇØ ±× ÀÛ¿ëÀ» ÀҴ´Ù. È¿¼Ò´Â »ýü¿¡ ³Î¸® ºÐÆ÷Çϸç, º¹ÀâÇÏ°í ´Ù¾çÇÑ ´ë»ç¹ÝÀÀÀ» Ã˸ÅÇϱ⠶§¹®¿¡ Á¾·ùµµ ¸¹´Ù. ¾Õ¼ ¸»ÇÑ ¹Ù¿Í °°ÀÌ ´ëºÎºÐÀÇ È¿¼Ò´Â ¼¼Æ÷³»¿¡ Á¸ÀçÇÏÁö¸¸, Ç÷¾×°ú ±×¿ÜÀÇ °£Áú¾×¿¡ µé¾î Àֱ⵵ ÇÏ°í ¼ÒÈÈ¿¼Ò·ùó·³ ü¿Ü·Î ºÐºñµÇ´Â °Íµµ ÀÖ´Ù. |
||
| ¿µ¹® | enzyme-linked immunoabsorbent assay | ÇÑ±Û | È¿¼Ò¸é¿ªÃøÁ¤¹ý |
|---|---|---|---|
| ¼³¸í | È¿¼Ò°áÇո鿪ÈíÂøÁ¦ °ËÁ¤¹ýÀ¸·Î ¹ø¿ªµÇ°í ÀÖ´Ù. ÀÌ ¹ýÀº Ç׿ø(¶Ç´Â Ç×ü)¿¡ ¾ËÄ®¸® Æ÷½ºÆÄŸ¾ÆÁ¦ ¶Ç´Â Æä¸£¿Á½Ãµð¾ÆÁ¦ µîÀÇ »ê¼Ò¸¦ °áÇÕ½ÃÄÑ µÎ°í ±× »ê¼ÒȰ¼ºÀ» ÁöÇ¥·Î »ï¾Æ Ç׿øÇ×ü¹ÝÀÀÀÇ Á¤µµ¸¦ ¾È ´ÙÀ½ ¿©±â¿¡¼ Ç׿ø(¶Ç´Â Ç×ü)ÀÇ ¾çÀ» ±¸ÇÏ´Â °ÍÀÌ´Ù. ÀÌ ¹ýÀÇ ÀÌÁ¡À¸·Î¼ °í°¨µµ, Á¶ÀÛÀÇ °£´ÜÇÔ ¹× ¹æ»ç¼±¸é¿ªÃøÁ¤¹ýó·³ ¹æ»ç¼º¹°ÁúÀ» »ç¿ëÇÏÁö ¾Ê¾Æµµ µÈ´Ù´Â Á¡À» µé ¼ö ÀÖ´Ù. È£¸£¸óÀ̳ª ¸é¿ª±Û·ÎºÒ¸°ÀÇ Á¤·®¹ýÀ¸·Î¼ ÀÀ¿ë µÇ°í ÀÖÀ¸¸ç ÃøÁ¤¿ë ŰƮµµ ½ÃÆÇµÇ°í ÀÌÀÖ´Ù. |
||
| PACE | Pacing and Clinical Electrophysiology; paired basic amino acid cleaving enzyme; personalized aerobic... |
|---|---|
| ACEI | angiotensin-converting enzyme inhibitor |
| CEI | character education inquiry; converting enzyme inhibitor |
| ESI | elastase-specific inhibitor; enzyme substrate inhibitor; epidural steroid injection |
| BPTI | basic pancreatic trypsin inhibitor; basic polyvalent trypsin inhibitor; bovine pancreatic trypsin in... |
| ACE inhibitor | angiotensin converting enzyme inhibitor |
|---|---|
| ACEI | Angiotensin Converting Enzyme Inhibitor |
| CEI | Converting enzyme inhibitor |
| ACE | ANG I converting enzyme |
| ACE | ANGIOTENSIN CONVERTING ENZYME |
| angiotensin-converting enzyme inhibitor | <pharmacology> A class of drugs used in the treatment of hypertension and heart failure. They exert their haemodynamic effect mainly by inhibiting the renin-angiotensin system and produce a reduction of peripheral arterial resistance. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (14 Aug 2000) |
|---|---|
| angiotensin-converting enzyme | <enzyme> This hydrolase enzyme cleaves the decapeptide angiotensin I (biologically inactive) to form active angiotensin II by angiotensin-converting enzyme which removes a dipeptide (histidylleucine) from angiotensin I. Angiotensin II causes contraction of vascular smooth muscle and thus raises blood pressure and stimulates aldosterone release from the adrenal glands. Angiotensin is finally broken down by angiotensinases. Elevations in angiotensin converting enzyme are seen sarcoidosis, histoplasmosis, alcoholic cirrhosis, asbestosis, berylliosis, diabetes, Hodgkin's disease, hyperthyroidism, amyloidosis, primary biliary cirrhosis, idiopathic pulmonary fibrosis, pulmonary embolism, scleroderma, silicosis, tuberculosis, Gaucher's disease and leprosy. The normal values are 18 to 67 U/ml over 20 years of age (people under 20 have higher levels). Drugs that inhibit ACE are used to treat hypertension and congestive heart failure. See: angiotensin-converting enzyme inhibitor Acronym: ACE (12 Aug 2000) |
| angiotensin-converting enzyme secretase | <enzyme> Converts ace from a membrane-bound to a soluble form; not inhibited by thiol, serine or acid enzyme inhibitor but is inhibited by edta and 1,10-phenanthroline Registry number: EC 3.4.99.- Synonym: ace secretase (26 Jun 1999) |
| interleukin-1 converting enzyme | <biochemistry> Cytoplasmic cysteine protease that is uniquely responsible for cleaving proIL-1_ (31 or 33 kD) into mature IL-1_ (17.5 kD), the active cytokine is then released by a nonstandard mechanism (there is no signal sequence and it does not pass through the Golgi). The enzyme seems to be composed of two nonidentical subunits derived from a single proenzyme. The ICE gene has some homology with the ced 9 gene of C. Elegans, the product of which is involved in mediating cell death by apoptosis. (11 Mar 1998) |
| vasopressin-converting aminopeptidase | <enzyme> Activity found in brain which converts vasopressin into centrally active metabolites Registry number: EC 3.4.11.- Synonym: vp-c aminopeptidase (26 Jun 1999) |
| dynorphin-converting endopeptidase | <enzyme> Enzyme from human cerebrospinal fluid; cleaves dynorphin a and b and neoendorphin at the arg(6)-arg(7) or arg(6)-lys(7) bonds Registry number: EC 3.4.21.- Synonym: dynorphin-neo-endorphin endopeptidase, dc-endopeptidase (26 Jun 1999) |
| urokinase-converting protease | <enzyme> Degrades synthetic urokinase substrates and stimulates urokinase Registry number: EC 3.4.21.- Synonym: urokinase cofactor (26 Jun 1999) |
| a1-trypsin inhibitor | A glycoprotein that is the major protease inhibitor of human serum, is synthesised in the liver, and is genetically polymorphic due to the presence of over 20 alleles; individuals appropriately homozygous are deficient in a1-trypsin and are predisposed to pulmonary emphysema and juvenile hepatic cirrhosis because of alterations in the amino acid and sialic acid components of the glycoprotein. A1-Antitrypsin also inhibits thrombin. Synonym: a1-trypsin inhibitor, human a1-proteinase inhibitor. (05 Mar 2000) |
| ACE inhibitor | <pharmacology> A group of antihypertensive medications that work by inhibiting an enzyme (angiotensin-converting enzyme) that is important in the regulation of blood pressure. Studies have also indicated that it may help prevent or slow the progression of kidney disease in patients with diabetes. Examples include: captopril, ramipril, enalapril, losartan potassium, bepridil and lisinopril. (12 Mar 1998) |
| aldose reductase inhibitor | <pharmacology> A class of drugs being studied as a way to prevent eye and nerve damage in people with diabetes. Aldose reductase is an enzyme that is normally present in the eye and in many other parts of the body. It helps change glucose (sugar) into a sugar alcohol called sorbitol. Too much sorbitol trapped in eye and nerve cells can damage these cells, leading to retinopathy and neuropathy. Drugs that prevent or slow (inhibit) the action of aldose reductase are being studied as a way to prevent or delay these complications of diabetes. (09 Oct 1997) |
| aromatase inhibitor | Drugs, such as aminoglutethimide, that inhibit aromatase, an enzyme used in the synthesis of oestrogens. (05 Mar 2000) |
| beta-lactamase inhibitor | <pharmacology> Drugs such as clavulanic acid, which are used to inhibit bacterial beta-lactamases; often used with a penicillin or cephalosporin to overcome drug resistance. (05 Mar 2000) |
| Bowman-Birk inhibitor | A polypeptide that will inhibit both trypsin and chymotrypsin. (05 Mar 2000) |
| C1 esterase inhibitor | An a2-neuraminoglycoprotein that inhibits the enzymatic activity of C1 esterase, the activated first component of complement. A deficiency of this inhibitor results in a lack of inhibition of C1r and C1s leading to uncontrolled activation of the complement cascade and oedema. (05 Mar 2000) |
| carbonate dehydratase inhibitor | An agent, usually chemically related to the sulfonamides, that inhibits the activity of carbonate dehydratase, producing a general decrease in the formation of H2CO3 in the tissues. See: acetazolamide, dichlorphenamide. Synonym: carbonic anhydrase inhibitor. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|